nodes	percent_of_prediction	percent_of_DWPC	metapath
Reboxetine—ABCB1—Mitoxantrone—lymphatic system cancer	0.0979	0.207	CbGbCtD
Reboxetine—CYP3A4—Cytarabine—lymphatic system cancer	0.0852	0.18	CbGbCtD
Reboxetine—CYP3A4—Teniposide—lymphatic system cancer	0.0839	0.177	CbGbCtD
Reboxetine—ABCB1—Vincristine—lymphatic system cancer	0.0674	0.142	CbGbCtD
Reboxetine—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0587	0.124	CbGbCtD
Reboxetine—ABCB1—Methotrexate—lymphatic system cancer	0.0408	0.086	CbGbCtD
Reboxetine—CYP3A4—Vincristine—lymphatic system cancer	0.0404	0.0852	CbGbCtD
Reboxetine—Infection—Fludarabine—lymphatic system cancer	0.00161	0.00306	CcSEcCtD
Reboxetine—Erectile dysfunction—Vincristine—lymphatic system cancer	0.0016	0.00304	CcSEcCtD
Reboxetine—Decreased appetite—Teniposide—lymphatic system cancer	0.0016	0.00304	CcSEcCtD
Reboxetine—Vomiting—Mechlorethamine—lymphatic system cancer	0.00159	0.00302	CcSEcCtD
Reboxetine—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00159	0.00302	CcSEcCtD
Reboxetine—Urinary tract infection—Carmustine—lymphatic system cancer	0.00158	0.003	CcSEcCtD
Reboxetine—Rash—Mechlorethamine—lymphatic system cancer	0.00157	0.00299	CcSEcCtD
Reboxetine—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00157	0.00299	CcSEcCtD
Reboxetine—Weight decreased—Vincristine—lymphatic system cancer	0.00157	0.00299	CcSEcCtD
Reboxetine—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00156	0.00297	CcSEcCtD
Reboxetine—Speech disorder—Methotrexate—lymphatic system cancer	0.00156	0.00297	CcSEcCtD
Reboxetine—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.00156	0.00296	CcSEcCtD
Reboxetine—Anorexia—Fludarabine—lymphatic system cancer	0.00154	0.00293	CcSEcCtD
Reboxetine—Weight decreased—Mitoxantrone—lymphatic system cancer	0.00153	0.00291	CcSEcCtD
Reboxetine—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	0.00153	0.0029	CcSEcCtD
Reboxetine—Feeling abnormal—Teniposide—lymphatic system cancer	0.00152	0.00288	CcSEcCtD
Reboxetine—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.0015	0.00286	CcSEcCtD
Reboxetine—Chills—Bleomycin—lymphatic system cancer	0.0015	0.00285	CcSEcCtD
Reboxetine—Sweating—Vincristine—lymphatic system cancer	0.00149	0.00282	CcSEcCtD
Reboxetine—Nausea—Mechlorethamine—lymphatic system cancer	0.00148	0.00282	CcSEcCtD
Reboxetine—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.00147	0.00279	CcSEcCtD
Reboxetine—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.00147	0.00279	CcSEcCtD
Reboxetine—Urticaria—Teniposide—lymphatic system cancer	0.00146	0.00278	CcSEcCtD
Reboxetine—Glossitis—Methotrexate—lymphatic system cancer	0.00146	0.00277	CcSEcCtD
Reboxetine—Body temperature increased—Teniposide—lymphatic system cancer	0.00145	0.00277	CcSEcCtD
Reboxetine—Abdominal pain—Teniposide—lymphatic system cancer	0.00145	0.00277	CcSEcCtD
Reboxetine—Paraesthesia—Fludarabine—lymphatic system cancer	0.00145	0.00276	CcSEcCtD
Reboxetine—Hallucination—Carmustine—lymphatic system cancer	0.00145	0.00276	CcSEcCtD
Reboxetine—Hyperuricaemia—Methotrexate—lymphatic system cancer	0.00145	0.00275	CcSEcCtD
Reboxetine—Sweating—Mitoxantrone—lymphatic system cancer	0.00145	0.00275	CcSEcCtD
Reboxetine—Dyspnoea—Fludarabine—lymphatic system cancer	0.00144	0.00274	CcSEcCtD
Reboxetine—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00143	0.00272	CcSEcCtD
Reboxetine—Dyspepsia—Fludarabine—lymphatic system cancer	0.00142	0.00271	CcSEcCtD
Reboxetine—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00142	0.00269	CcSEcCtD
Reboxetine—Decreased appetite—Fludarabine—lymphatic system cancer	0.00141	0.00267	CcSEcCtD
Reboxetine—Visual impairment—Carmustine—lymphatic system cancer	0.0014	0.00267	CcSEcCtD
Reboxetine—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.0014	0.00266	CcSEcCtD
Reboxetine—Hallucination—Vincristine—lymphatic system cancer	0.00138	0.00263	CcSEcCtD
Reboxetine—Constipation—Fludarabine—lymphatic system cancer	0.00138	0.00263	CcSEcCtD
Reboxetine—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00138	0.00262	CcSEcCtD
Reboxetine—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00137	0.00261	CcSEcCtD
Reboxetine—Blood uric acid increased—Methotrexate—lymphatic system cancer	0.00137	0.0026	CcSEcCtD
Reboxetine—Respiratory failure—Methotrexate—lymphatic system cancer	0.00137	0.0026	CcSEcCtD
Reboxetine—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00137	0.0026	CcSEcCtD
Reboxetine—Urethral disorder—Vincristine—lymphatic system cancer	0.00136	0.00259	CcSEcCtD
Reboxetine—Eye disorder—Carmustine—lymphatic system cancer	0.00136	0.00259	CcSEcCtD
Reboxetine—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00136	0.00258	CcSEcCtD
Reboxetine—Hypersensitivity—Teniposide—lymphatic system cancer	0.00136	0.00258	CcSEcCtD
Reboxetine—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00135	0.00256	CcSEcCtD
Reboxetine—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00134	0.00256	CcSEcCtD
Reboxetine—Anaemia—Bleomycin—lymphatic system cancer	0.00134	0.00255	CcSEcCtD
Reboxetine—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00133	0.00253	CcSEcCtD
Reboxetine—Asthenia—Teniposide—lymphatic system cancer	0.00132	0.00251	CcSEcCtD
Reboxetine—Malaise—Bleomycin—lymphatic system cancer	0.00131	0.00249	CcSEcCtD
Reboxetine—Leukopenia—Bleomycin—lymphatic system cancer	0.0013	0.00247	CcSEcCtD
Reboxetine—Cardiac disorder—Vincristine—lymphatic system cancer	0.00129	0.00245	CcSEcCtD
Reboxetine—Body temperature increased—Fludarabine—lymphatic system cancer	0.00128	0.00243	CcSEcCtD
Reboxetine—Mental disorder—Carmustine—lymphatic system cancer	0.00128	0.00243	CcSEcCtD
Reboxetine—Malnutrition—Carmustine—lymphatic system cancer	0.00127	0.00241	CcSEcCtD
Reboxetine—Angiopathy—Vincristine—lymphatic system cancer	0.00126	0.0024	CcSEcCtD
Reboxetine—Diarrhoea—Teniposide—lymphatic system cancer	0.00126	0.00239	CcSEcCtD
Reboxetine—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00125	0.00238	CcSEcCtD
Reboxetine—Chest pain—Bleomycin—lymphatic system cancer	0.00124	0.00235	CcSEcCtD
Reboxetine—Discomfort—Bleomycin—lymphatic system cancer	0.00122	0.00232	CcSEcCtD
Reboxetine—Mental disorder—Vincristine—lymphatic system cancer	0.00122	0.00232	CcSEcCtD
Reboxetine—Chills—Mitoxantrone—lymphatic system cancer	0.00122	0.00231	CcSEcCtD
Reboxetine—Confusional state—Bleomycin—lymphatic system cancer	0.0012	0.00227	CcSEcCtD
Reboxetine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00119	0.00227	CcSEcCtD
Reboxetine—Tremor—Carmustine—lymphatic system cancer	0.00119	0.00226	CcSEcCtD
Reboxetine—Infection—Bleomycin—lymphatic system cancer	0.00118	0.00224	CcSEcCtD
Reboxetine—Anaemia—Carmustine—lymphatic system cancer	0.00117	0.00223	CcSEcCtD
Reboxetine—Vomiting—Teniposide—lymphatic system cancer	0.00117	0.00223	CcSEcCtD
Reboxetine—Agitation—Carmustine—lymphatic system cancer	0.00117	0.00222	CcSEcCtD
Reboxetine—Asthenia—Fludarabine—lymphatic system cancer	0.00116	0.00221	CcSEcCtD
Reboxetine—Rash—Teniposide—lymphatic system cancer	0.00116	0.00221	CcSEcCtD
Reboxetine—Dermatitis—Teniposide—lymphatic system cancer	0.00116	0.0022	CcSEcCtD
Reboxetine—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00115	0.0022	CcSEcCtD
Reboxetine—Headache—Teniposide—lymphatic system cancer	0.00115	0.00219	CcSEcCtD
Reboxetine—Leukopenia—Carmustine—lymphatic system cancer	0.00114	0.00216	CcSEcCtD
Reboxetine—Anorexia—Bleomycin—lymphatic system cancer	0.00113	0.00215	CcSEcCtD
Reboxetine—Anaemia—Vincristine—lymphatic system cancer	0.00112	0.00213	CcSEcCtD
Reboxetine—Agitation—Vincristine—lymphatic system cancer	0.00111	0.00212	CcSEcCtD
Reboxetine—Hypotension—Bleomycin—lymphatic system cancer	0.00111	0.00211	CcSEcCtD
Reboxetine—Diarrhoea—Fludarabine—lymphatic system cancer	0.00111	0.0021	CcSEcCtD
Reboxetine—Hypertension—Carmustine—lymphatic system cancer	0.0011	0.00208	CcSEcCtD
Reboxetine—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00109	0.00208	CcSEcCtD
Reboxetine—Nausea—Teniposide—lymphatic system cancer	0.00109	0.00208	CcSEcCtD
Reboxetine—Anaemia—Mitoxantrone—lymphatic system cancer	0.00109	0.00207	CcSEcCtD
Reboxetine—Vertigo—Vincristine—lymphatic system cancer	0.00109	0.00207	CcSEcCtD
Reboxetine—Leukopenia—Vincristine—lymphatic system cancer	0.00108	0.00206	CcSEcCtD
Reboxetine—Chest pain—Carmustine—lymphatic system cancer	0.00108	0.00205	CcSEcCtD
Reboxetine—Anxiety—Carmustine—lymphatic system cancer	0.00108	0.00205	CcSEcCtD
Reboxetine—Paraesthesia—Bleomycin—lymphatic system cancer	0.00106	0.00202	CcSEcCtD
Reboxetine—Malaise—Mitoxantrone—lymphatic system cancer	0.00106	0.00202	CcSEcCtD
Reboxetine—Dyspnoea—Bleomycin—lymphatic system cancer	0.00106	0.00201	CcSEcCtD
Reboxetine—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00106	0.00201	CcSEcCtD
Reboxetine—Hypertension—Vincristine—lymphatic system cancer	0.00105	0.00199	CcSEcCtD
Reboxetine—Confusional state—Carmustine—lymphatic system cancer	0.00104	0.00198	CcSEcCtD
Reboxetine—Decreased appetite—Bleomycin—lymphatic system cancer	0.00103	0.00196	CcSEcCtD
Reboxetine—Infection—Carmustine—lymphatic system cancer	0.00103	0.00196	CcSEcCtD
Reboxetine—Vomiting—Fludarabine—lymphatic system cancer	0.00103	0.00196	CcSEcCtD
Reboxetine—Rash—Fludarabine—lymphatic system cancer	0.00102	0.00194	CcSEcCtD
Reboxetine—Dermatitis—Fludarabine—lymphatic system cancer	0.00102	0.00194	CcSEcCtD
Reboxetine—Hypertension—Mitoxantrone—lymphatic system cancer	0.00102	0.00194	CcSEcCtD
Reboxetine—Headache—Fludarabine—lymphatic system cancer	0.00101	0.00193	CcSEcCtD
Reboxetine—Tachycardia—Carmustine—lymphatic system cancer	0.00101	0.00192	CcSEcCtD
Reboxetine—Chest pain—Mitoxantrone—lymphatic system cancer	0.001	0.00191	CcSEcCtD
Reboxetine—Anxiety—Mitoxantrone—lymphatic system cancer	0.001	0.0019	CcSEcCtD
Reboxetine—Discomfort—Mitoxantrone—lymphatic system cancer	0.000992	0.00189	CcSEcCtD
Reboxetine—Anorexia—Carmustine—lymphatic system cancer	0.000987	0.00188	CcSEcCtD
Reboxetine—Infection—Vincristine—lymphatic system cancer	0.000982	0.00187	CcSEcCtD
Reboxetine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000977	0.00186	CcSEcCtD
Reboxetine—Confusional state—Mitoxantrone—lymphatic system cancer	0.00097	0.00185	CcSEcCtD
Reboxetine—Nervous system disorder—Vincristine—lymphatic system cancer	0.000969	0.00184	CcSEcCtD
Reboxetine—Hypotension—Carmustine—lymphatic system cancer	0.000967	0.00184	CcSEcCtD
Reboxetine—Nausea—Fludarabine—lymphatic system cancer	0.000961	0.00183	CcSEcCtD
Reboxetine—Infection—Mitoxantrone—lymphatic system cancer	0.000956	0.00182	CcSEcCtD
Reboxetine—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000955	0.00182	CcSEcCtD
Reboxetine—Shock—Mitoxantrone—lymphatic system cancer	0.000947	0.0018	CcSEcCtD
Reboxetine—Urticaria—Bleomycin—lymphatic system cancer	0.000942	0.00179	CcSEcCtD
Reboxetine—Anorexia—Vincristine—lymphatic system cancer	0.000942	0.00179	CcSEcCtD
Reboxetine—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000939	0.00179	CcSEcCtD
Reboxetine—Body temperature increased—Bleomycin—lymphatic system cancer	0.000938	0.00178	CcSEcCtD
Reboxetine—Insomnia—Carmustine—lymphatic system cancer	0.000936	0.00178	CcSEcCtD
Reboxetine—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000935	0.00178	CcSEcCtD
Reboxetine—Irritability—Methotrexate—lymphatic system cancer	0.000931	0.00177	CcSEcCtD
Reboxetine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00093	0.00177	CcSEcCtD
Reboxetine—Paraesthesia—Carmustine—lymphatic system cancer	0.00093	0.00177	CcSEcCtD
Reboxetine—Hypotension—Vincristine—lymphatic system cancer	0.000923	0.00176	CcSEcCtD
Reboxetine—Dyspnoea—Carmustine—lymphatic system cancer	0.000923	0.00175	CcSEcCtD
Reboxetine—Somnolence—Carmustine—lymphatic system cancer	0.00092	0.00175	CcSEcCtD
Reboxetine—Anorexia—Mitoxantrone—lymphatic system cancer	0.000917	0.00174	CcSEcCtD
Reboxetine—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000901	0.00171	CcSEcCtD
Reboxetine—Decreased appetite—Carmustine—lymphatic system cancer	0.0009	0.00171	CcSEcCtD
Reboxetine—Hypotension—Mitoxantrone—lymphatic system cancer	0.000899	0.00171	CcSEcCtD
Reboxetine—Insomnia—Vincristine—lymphatic system cancer	0.000894	0.0017	CcSEcCtD
Reboxetine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000894	0.0017	CcSEcCtD
Reboxetine—Paraesthesia—Vincristine—lymphatic system cancer	0.000887	0.00169	CcSEcCtD
Reboxetine—Constipation—Carmustine—lymphatic system cancer	0.000885	0.00168	CcSEcCtD
Reboxetine—Breast disorder—Methotrexate—lymphatic system cancer	0.000882	0.00168	CcSEcCtD
Reboxetine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000874	0.00166	CcSEcCtD
Reboxetine—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000864	0.00164	CcSEcCtD
Reboxetine—Decreased appetite—Vincristine—lymphatic system cancer	0.000859	0.00163	CcSEcCtD
Reboxetine—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000858	0.00163	CcSEcCtD
Reboxetine—Somnolence—Mitoxantrone—lymphatic system cancer	0.000856	0.00163	CcSEcCtD
Reboxetine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000853	0.00162	CcSEcCtD
Reboxetine—Feeling abnormal—Carmustine—lymphatic system cancer	0.000853	0.00162	CcSEcCtD
Reboxetine—Asthenia—Bleomycin—lymphatic system cancer	0.000851	0.00162	CcSEcCtD
Reboxetine—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000847	0.00161	CcSEcCtD
Reboxetine—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000847	0.00161	CcSEcCtD
Reboxetine—Constipation—Vincristine—lymphatic system cancer	0.000845	0.00161	CcSEcCtD
Reboxetine—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000837	0.00159	CcSEcCtD
Reboxetine—Constipation—Mitoxantrone—lymphatic system cancer	0.000823	0.00156	CcSEcCtD
Reboxetine—Abdominal pain—Carmustine—lymphatic system cancer	0.000818	0.00156	CcSEcCtD
Reboxetine—Body temperature increased—Carmustine—lymphatic system cancer	0.000818	0.00156	CcSEcCtD
Reboxetine—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000808	0.00154	CcSEcCtD
Reboxetine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000793	0.00151	CcSEcCtD
Reboxetine—Dysuria—Methotrexate—lymphatic system cancer	0.000788	0.0015	CcSEcCtD
Reboxetine—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000787	0.0015	CcSEcCtD
Reboxetine—Abdominal pain—Vincristine—lymphatic system cancer	0.000781	0.00149	CcSEcCtD
Reboxetine—Body temperature increased—Vincristine—lymphatic system cancer	0.000781	0.00149	CcSEcCtD
Reboxetine—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000777	0.00148	CcSEcCtD
Reboxetine—Urticaria—Mitoxantrone—lymphatic system cancer	0.000765	0.00145	CcSEcCtD
Reboxetine—Hypersensitivity—Carmustine—lymphatic system cancer	0.000763	0.00145	CcSEcCtD
Reboxetine—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000761	0.00145	CcSEcCtD
Reboxetine—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000761	0.00145	CcSEcCtD
Reboxetine—Vomiting—Bleomycin—lymphatic system cancer	0.000754	0.00143	CcSEcCtD
Reboxetine—Infestation—Methotrexate—lymphatic system cancer	0.000752	0.00143	CcSEcCtD
Reboxetine—Infestation NOS—Methotrexate—lymphatic system cancer	0.000752	0.00143	CcSEcCtD
Reboxetine—Rash—Bleomycin—lymphatic system cancer	0.000748	0.00142	CcSEcCtD
Reboxetine—Dermatitis—Bleomycin—lymphatic system cancer	0.000747	0.00142	CcSEcCtD
Reboxetine—Asthenia—Carmustine—lymphatic system cancer	0.000743	0.00141	CcSEcCtD
Reboxetine—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000731	0.00139	CcSEcCtD
Reboxetine—Hypersensitivity—Vincristine—lymphatic system cancer	0.000728	0.00138	CcSEcCtD
Reboxetine—Sweating—Methotrexate—lymphatic system cancer	0.000721	0.00137	CcSEcCtD
Reboxetine—Epistaxis—Methotrexate—lymphatic system cancer	0.000709	0.00135	CcSEcCtD
Reboxetine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000709	0.00135	CcSEcCtD
Reboxetine—Asthenia—Vincristine—lymphatic system cancer	0.000709	0.00135	CcSEcCtD
Reboxetine—Diarrhoea—Carmustine—lymphatic system cancer	0.000708	0.00135	CcSEcCtD
Reboxetine—Nausea—Bleomycin—lymphatic system cancer	0.000704	0.00134	CcSEcCtD
Reboxetine—Asthenia—Mitoxantrone—lymphatic system cancer	0.000691	0.00131	CcSEcCtD
Reboxetine—Dizziness—Carmustine—lymphatic system cancer	0.000685	0.0013	CcSEcCtD
Reboxetine—Diarrhoea—Vincristine—lymphatic system cancer	0.000676	0.00129	CcSEcCtD
Reboxetine—Pharyngitis—Methotrexate—lymphatic system cancer	0.00067	0.00127	CcSEcCtD
Reboxetine—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000667	0.00127	CcSEcCtD
Reboxetine—Urethral disorder—Methotrexate—lymphatic system cancer	0.000662	0.00126	CcSEcCtD
Reboxetine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000658	0.00125	CcSEcCtD
Reboxetine—Vomiting—Carmustine—lymphatic system cancer	0.000658	0.00125	CcSEcCtD
Reboxetine—Dizziness—Vincristine—lymphatic system cancer	0.000653	0.00124	CcSEcCtD
Reboxetine—Rash—Carmustine—lymphatic system cancer	0.000653	0.00124	CcSEcCtD
Reboxetine—Dermatitis—Carmustine—lymphatic system cancer	0.000652	0.00124	CcSEcCtD
Reboxetine—Visual impairment—Methotrexate—lymphatic system cancer	0.00065	0.00124	CcSEcCtD
Reboxetine—Headache—Carmustine—lymphatic system cancer	0.000649	0.00123	CcSEcCtD
Reboxetine—Eye disorder—Methotrexate—lymphatic system cancer	0.000631	0.0012	CcSEcCtD
Reboxetine—Tinnitus—Methotrexate—lymphatic system cancer	0.000629	0.0012	CcSEcCtD
Reboxetine—Vomiting—Vincristine—lymphatic system cancer	0.000628	0.00119	CcSEcCtD
Reboxetine—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000626	0.00119	CcSEcCtD
Reboxetine—Rash—Vincristine—lymphatic system cancer	0.000623	0.00118	CcSEcCtD
Reboxetine—Dermatitis—Vincristine—lymphatic system cancer	0.000623	0.00118	CcSEcCtD
Reboxetine—Headache—Vincristine—lymphatic system cancer	0.000619	0.00118	CcSEcCtD
Reboxetine—Nausea—Carmustine—lymphatic system cancer	0.000615	0.00117	CcSEcCtD
Reboxetine—Angiopathy—Methotrexate—lymphatic system cancer	0.000612	0.00116	CcSEcCtD
Reboxetine—Vomiting—Mitoxantrone—lymphatic system cancer	0.000612	0.00116	CcSEcCtD
Reboxetine—Immune system disorder—Methotrexate—lymphatic system cancer	0.00061	0.00116	CcSEcCtD
Reboxetine—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000608	0.00116	CcSEcCtD
Reboxetine—Rash—Mitoxantrone—lymphatic system cancer	0.000607	0.00115	CcSEcCtD
Reboxetine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000606	0.00115	CcSEcCtD
Reboxetine—Chills—Methotrexate—lymphatic system cancer	0.000606	0.00115	CcSEcCtD
Reboxetine—Headache—Mitoxantrone—lymphatic system cancer	0.000603	0.00115	CcSEcCtD
Reboxetine—Mental disorder—Methotrexate—lymphatic system cancer	0.000591	0.00112	CcSEcCtD
Reboxetine—Malnutrition—Methotrexate—lymphatic system cancer	0.000588	0.00112	CcSEcCtD
Reboxetine—Nausea—Vincristine—lymphatic system cancer	0.000587	0.00112	CcSEcCtD
Reboxetine—Dysgeusia—Methotrexate—lymphatic system cancer	0.000575	0.00109	CcSEcCtD
Reboxetine—Nausea—Mitoxantrone—lymphatic system cancer	0.000572	0.00109	CcSEcCtD
Reboxetine—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000545	0.00104	CcSEcCtD
Reboxetine—Anaemia—Methotrexate—lymphatic system cancer	0.000543	0.00103	CcSEcCtD
Reboxetine—Malaise—Methotrexate—lymphatic system cancer	0.00053	0.00101	CcSEcCtD
Reboxetine—Vertigo—Methotrexate—lymphatic system cancer	0.000528	0.001	CcSEcCtD
Reboxetine—Leukopenia—Methotrexate—lymphatic system cancer	0.000526	0.001	CcSEcCtD
Reboxetine—Chest pain—Methotrexate—lymphatic system cancer	0.0005	0.000951	CcSEcCtD
Reboxetine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000497	0.000945	CcSEcCtD
Reboxetine—Discomfort—Methotrexate—lymphatic system cancer	0.000494	0.00094	CcSEcCtD
Reboxetine—Confusional state—Methotrexate—lymphatic system cancer	0.000483	0.000919	CcSEcCtD
Reboxetine—Infection—Methotrexate—lymphatic system cancer	0.000476	0.000906	CcSEcCtD
Reboxetine—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00047	0.000894	CcSEcCtD
Reboxetine—Skin disorder—Methotrexate—lymphatic system cancer	0.000466	0.000886	CcSEcCtD
Reboxetine—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000464	0.000881	CcSEcCtD
Reboxetine—Anorexia—Methotrexate—lymphatic system cancer	0.000457	0.000869	CcSEcCtD
Reboxetine—Hypotension—Methotrexate—lymphatic system cancer	0.000448	0.000852	CcSEcCtD
Reboxetine—Insomnia—Methotrexate—lymphatic system cancer	0.000434	0.000825	CcSEcCtD
Reboxetine—Paraesthesia—Methotrexate—lymphatic system cancer	0.000431	0.000819	CcSEcCtD
Reboxetine—Dyspnoea—Methotrexate—lymphatic system cancer	0.000427	0.000813	CcSEcCtD
Reboxetine—Somnolence—Methotrexate—lymphatic system cancer	0.000426	0.000811	CcSEcCtD
Reboxetine—Dyspepsia—Methotrexate—lymphatic system cancer	0.000422	0.000803	CcSEcCtD
Reboxetine—Decreased appetite—Methotrexate—lymphatic system cancer	0.000417	0.000793	CcSEcCtD
Reboxetine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000414	0.000787	CcSEcCtD
Reboxetine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000395	0.000751	CcSEcCtD
Reboxetine—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000392	0.000746	CcSEcCtD
Reboxetine—Urticaria—Methotrexate—lymphatic system cancer	0.000381	0.000724	CcSEcCtD
Reboxetine—Abdominal pain—Methotrexate—lymphatic system cancer	0.000379	0.000721	CcSEcCtD
Reboxetine—Body temperature increased—Methotrexate—lymphatic system cancer	0.000379	0.000721	CcSEcCtD
Reboxetine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000353	0.000672	CcSEcCtD
Reboxetine—Asthenia—Methotrexate—lymphatic system cancer	0.000344	0.000654	CcSEcCtD
Reboxetine—Diarrhoea—Methotrexate—lymphatic system cancer	0.000328	0.000624	CcSEcCtD
Reboxetine—Dizziness—Methotrexate—lymphatic system cancer	0.000317	0.000603	CcSEcCtD
Reboxetine—Vomiting—Methotrexate—lymphatic system cancer	0.000305	0.00058	CcSEcCtD
Reboxetine—Rash—Methotrexate—lymphatic system cancer	0.000302	0.000575	CcSEcCtD
Reboxetine—Dermatitis—Methotrexate—lymphatic system cancer	0.000302	0.000574	CcSEcCtD
Reboxetine—Headache—Methotrexate—lymphatic system cancer	0.0003	0.000571	CcSEcCtD
Reboxetine—Nausea—Methotrexate—lymphatic system cancer	0.000285	0.000542	CcSEcCtD
